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We describe melioidosis associated with travel to 
Nigeria in a woman with diabetes, a major predisposing 
factor for this infection. With the prevalence of diabetes 
projected to increase dramatically in many developing 
countries, the global reach of melioidosis may expand.
The Patient 
A 46-year-old woman sought treatment in the 
emergency department of St Thomas’ Hospital, London, 
UK. She described a 2-day history of frontal headache, 
fever, and painful swelling in the right postauricular region. 
She had received a diagnosis of type 2 diabetes mellitus 5 
months before admission, for which she took metformin 
(500 mg 2×/d). She did not smoke or drink alcohol. She 
was born in Ogun State, Nigeria, and had moved to the 
United Kingdom at the age of 31 years. She recently had 
visited relatives in Sagamu City, Ogun State, and returned 
to the United Kingdom 6 weeks before onset of her illness. 
She had no history of travel outside the United Kingdom 
or Nigeria.
Examination at admission indicated a temperature of 
39.5°C, a heart rate of 108 beats per minute, and a blood 
pressure level of 132/84 mm Hg. Other examination 
ﬁ   ndings were unremarkable, apart from a tender, ﬁ  rm, 
erythematous, and hot swollen area (4 cm × 3 cm) in the 
right postauricular region. Initial investigations found a 
leukocyte count of 6.1 × 109 cells/L (neutrophils 4.4 × 109 
cells/L) and a C-reactive protein level of 406 mg/L; renal 
and liver proﬁ  les were normal. Results of a hemoglobin 
A1c blood test for diabetes were 13%, which is consistent 
with poorly controlled diabetes, and results of an HIV test 
and malaria screen were both negative. Ultrasonography 
of the swollen area showed localized, superﬁ  cial, enlarged 
lymph nodes, posterior and inferior to the right pinna. 
Blood was drawn for culturing, and a course of intravenous 
ﬂ   ucloxacillin treatment was begun. Subsequently, the 
aerobic bottles of 2 sets of blood cultures were positive for 
gram-negative bacilli, and subculturing yielded an oxidase-
positive, gram-negative bacillus that grew rapidly on blood 
agar as a gray colony with a metallic sheen. The organism 
was subsequently identiﬁ  ed as Burkholderia pseudomallei 
(see characterization of blood culture isolate). The 
antimicrobial drug therapy was changed to intravenous 
co-amoxiclav (1.2 g 3×/d), and 3 days later, when the 
identiﬁ  cation of the organism was conﬁ  rmed, the patient’s 
treatment was switched to intravenous meropenem (2 
g 3×/d). Results of a computed tomography scan of the 
chest and abdomen were normal. The patient’s fever and 
lymphadenopathy subsequently resolved, and after 9 days 
of receiving meropenem, she was discharged with a 12-
week course of oral co-trimoxazole (1,920 mg daily). The 
patient did not attend her scheduled outpatient appointment. 
Two microbiology laboratory workers were judged 
to have had low-risk exposure to the organism before its 
identiﬁ  cation (1). They were counseled, and both chose 
not to receive antimicrobial drug prophylaxis. Serologic 
follow-up at 2 and 6 weeks postexposure for 1 worker 
showed no evidence of seroconversion to B. pseudomallei. 
The other did not attend her scheduled occupational health 
outpatient appointment.
Because the isolate could not be deﬁ  nitively identiﬁ  ed 
by using API20NE (bioMérieux, Marcy l’Etoile, France), 
it was sent to the UK Health Protection Agency reference 
laboratory for further analysis. The appearance of the 
organism in colonies on Ashdown agar was typical of 
B. pseudomallei. Moreover, the same identiﬁ  cation was 
reached through fatty acid methyl ester analysis by gas 
chromatography with the rapid bioterrorism database 
(MIDI Sherlock, Newark, NJ, USA). PCR ampliﬁ  cation, 
using primers that speciﬁ  cally detect the type III secretion 
system gene cluster of B. pseudomallei (2), produced the 
predicted 115-bp band for our isolate and the positive 
control,  B. pseudomallei strain 204 (3). Multilocus 
sequence typing, performed by using PCR ampliﬁ  cation 
conditions and primers as previously described (3), 
generated an allelic proﬁ  le (1, 1, 10, 2, 5, 2, 1) that was 
compared with those of strains of B. pseudomallei, B. 
mallei, and B. thailandensis stored in the database (http://
bpseudomallei.mlst.net). This proﬁ  le was unique among 
strains in the multilocus sequence typing database and 
therefore represents a novel sequence type (ST), ST707. 
An evolutionary analysis of ST707 with eBURST 
version 3 (http://eburst.mlst.net) suggested that it was 
most closely related to other strains of B. pseudomallei, 
including ST26 from Niger, ST82 from France, and ST7 
from Vietnam (Figure).
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B. pseudomallei is the causative agent of melioidosis, 
a severe illness usually characterized by fever, 
lymphadenopathy, and suppurative lesions in skin, liver, 
spleen or the lung. The organism is present in the soil 
to disease-endemic areas, and infection is thought to be 
acquired through breaks in the skin. The disease is endemic 
in many parts of Southeast Asia, with most cases being 
reported from Thailand (4). The infection is also a well-
recognized pathogen in the Northern Territory of Australia 
(5). In addition, sporadic cases have been described in 
Central and South America and the Paciﬁ  c islands. By 
contrast, strikingly few human cases of melioidosis have 
previously been reported in Africa. Wall et al. reported 
a case in The Gambia in a patient originally from Sierra 
Leone (6), and Bremmelgaard et al. noted a case in a 
Danish patient who had probably acquired the infection in 
Kenya (7). Despite the paucity of clinical cases reported 
from Africa, serologic surveys suggest that the organism is 
present in several countries, including Burkina Faso (8) and 
Uganda (9). Moreover, B. pseudomallei has been isolated 
from the soil and from animals in several African countries 
(10,11).
Conclusions
Although we cannot be certain, the patient reported 
here likely acquired her infection in Nigeria, the most 
populous country on the African continent. To our 
knowledge, no documented cases of melioidosis acquired 
in Nigeria have been reported. Most cases imported into the 
United Kingdom originate in Southeast Asia and the Indian 
subcontinent (12). Given the frequency of travel between 
the United Kingdom and Nigeria, the absence of imported 
cases from that country until now is striking. However, 
the patient’s strain appears to be related to a strain that 
was isolated from neighboring Niger ≈40 years earlier. 
Although the case we report here may represent a recent 
introduction of the organism into Nigeria, the disease 
may also be underdiagnosed because of the difﬁ  culty of 
identifying the organism in a resource-limited setting.
Although melioidosis may affect healthy persons, 
infection is strongly associated with underlying diseases 
and with diabetes in particular. In a case–control study in 
Thailand, diabetes was associated with an adjusted odds 
ratio of 12.9 (13). With the prevalence of diabetes projected 
to increase dramatically over the next few decades in the 
developing world (14), melioidosis may become more 
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Figure. eBURST analysis showing the evolutionary relation-
ship of sequence type (ST) 707 to Burkholderia pseudomallei, 
B. mallei, and B. thailandensis strains on the multilocus 
sequence typing database. Each circle and square (the latter 
indicate subfounders) represents an ST, with size being 
proportional to the number of isolations of that particular ST. 
The primary founder is ST48 (triangle). The lines directly 
linking STs represent strains that differ at a single locus in their 
allelic proﬁ  le.common in countries such as Nigeria. Finally, from a 
clinical standpoint, the patient reported here highlights the 
need to consider the diagnosis of melioidosis, even in the 
absence of travel to traditional disease-endemic countries.
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